{
    "organizations": [],
    "uuid": "02e7a95f0cd70e178b71c71da38edb723280ca12",
    "author": "",
    "url": "https://www.reuters.com/article/us-norway-biogen/norway-to-buy-biogens-spinraza-medicine-broadcaster-nrk-idUSKBN1FW0TR",
    "ord_in_thread": 0,
    "title": "Norway to buy Biogen's Spinraza medicine: broadcaster NRK",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "OSLO (Reuters) - Norwegian authorities will buy the rare-disease treatment Spinraza for patients from U.S. drugmaker Biogen Inc at a cost of 7 million Norwegian crowns ($880,381.33) per year per patient, public broadcaster NRK reported on Monday.\nSpinraza treats the rare, often fatal disease spinal muscular atrophy (SMA). Norwegian authorities will cover the costs for minors only.\n($1 = 7.9511 Norwegian crowns)\nReporting by Gwladys Fouche, editing by Terje Solsvik\n ",
    "published": "2018-02-12T12:07:00.000+02:00",
    "crawled": "2018-02-12T12:18:31.019+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "oslo",
        "reuters",
        "norwegian",
        "authority",
        "buy",
        "treatment",
        "spinraza",
        "patient",
        "drugmaker",
        "biogen",
        "inc",
        "cost",
        "million",
        "norwegian",
        "crown",
        "per",
        "year",
        "per",
        "patient",
        "public",
        "broadcaster",
        "nrk",
        "reported",
        "monday",
        "spinraza",
        "treat",
        "rare",
        "often",
        "fatal",
        "disease",
        "spinal",
        "muscular",
        "atrophy",
        "sma",
        "norwegian",
        "authority",
        "cover",
        "cost",
        "minor",
        "norwegian",
        "crown",
        "reporting",
        "gwladys",
        "fouche",
        "editing",
        "terje",
        "solsvik"
    ]
}